BridgeBio Reports Acoramidis Reduces Mortality and Hospitalizations in ATTR-CM Study

Reuters

2025/11/03

BridgeBio Reports Acoramidis Reduces Mortality and Hospitalizations in ATTR-CM Study

BridgeBio Pharma Inc. announced that data from the ATTRibute-CM study, evaluating its transthyretin stabilizer acoramidis (marketed as Attruby™), will be presented at the American Heart Association (AHA) Scientific Sessions 2025, scheduled for November 7-10, 2025, in New Orleans, LA. Ten moderated digital posters are set to cover various aspects of the ATTRibute-CM study, including the effect of acoramidis on all-cause mortality in patients with the p.V142I (V122I) variant of transthyretin amyloid cardiomyopathy (ATTR-CM), associations between serum transthyretin levels and cardiovascular outcomes, and the impact of acoramidis on clinical outcomes regardless of atrial fibrillation status. Additional topics include comparisons of mortality and cardiovascular-related hospitalizations between acoramidis and placebo, as well as analyses of healthcare resource utilization and outcomes related to other therapies. The results are scheduled to be presented at the upcoming conference and have not yet been disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566844-en) on November 03, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2580746290"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580746290\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580746290?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580746290","market":"fut","top_or_hot":-1,"title":"BridgeBio Reports Acoramidis Reduces Mortality and Hospitalizations in ATTR-CM Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BridgeBio Reports Acoramidis Reduces Mortality and Hospitalizations in ATTR-CM Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/BBIO\">BridgeBio Pharma</a> Inc. announced that data from the ATTRibute-CM study, evaluating its transthyretin stabilizer acoramidis (marketed as Attruby™), will be presented at the American Heart Association (AHA) Scientific Sessions 2025, scheduled for November 7-10, 2025, in New Orleans, LA. Ten moderated digital posters are set to cover various aspects of the ATTRibute-CM study, including the effect of acoramidis on all-cause mortality in patients with the p.V142I (V122I) variant of transthyretin amyloid cardiomyopathy (ATTR-CM), associations between serum transthyretin levels and cardiovascular outcomes, and the impact of acoramidis on clinical outcomes regardless of atrial fibrillation status. Additional topics include comparisons of mortality and cardiovascular-related hospitalizations between acoramidis and placebo, as well as analyses of healthcare resource utilization and outcomes related to other therapies. The results are scheduled to be presented at the upcoming conference and have not yet been disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566844-en) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BridgeBio Reports Acoramidis Reduces Mortality and Hospitalizations in ATTR-CM Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBridgeBio Reports Acoramidis Reduces Mortality and Hospitalizations in ATTR-CM Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-03 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BridgeBio Reports Acoramidis Reduces Mortality and Hospitalizations in ATTR-CM Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/BBIO\">BridgeBio Pharma</a> Inc. announced that data from the ATTRibute-CM study, evaluating its transthyretin stabilizer acoramidis (marketed as Attruby™), will be presented at the American Heart Association (AHA) Scientific Sessions 2025, scheduled for November 7-10, 2025, in New Orleans, LA. Ten moderated digital posters are set to cover various aspects of the ATTRibute-CM study, including the effect of acoramidis on all-cause mortality in patients with the p.V142I (V122I) variant of transthyretin amyloid cardiomyopathy (ATTR-CM), associations between serum transthyretin levels and cardiovascular outcomes, and the impact of acoramidis on clinical outcomes regardless of atrial fibrillation status. Additional topics include comparisons of mortality and cardiovascular-related hospitalizations between acoramidis and placebo, as well as analyses of healthcare resource utilization and outcomes related to other therapies. The results are scheduled to be presented at the upcoming conference and have not yet been disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566844-en) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL1dKDLf:1","article_id":"2580746290","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580746290","pubTimestamp":1762173029,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BridgeBio Pharma Inc. announced that data from the ATTRibute-CM study, evaluating its transthyretin stabilizer acoramidis , will be presented at the American Heart Association  Scientific Sessions 2025, scheduled for November 7-10, 2025, in New Orleans, LA. Ten moderated digital posters are set to cover various aspects of the ATTRibute-CM study, including the effect of acoramidis on all-cause mortality in patients with the p.V142I  variant of transthyretin amyloid cardiomyopathy , associations between serum transthyretin levels and cardiovascular outcomes, and the impact of acoramidis on clinical outcomes regardless of atrial fibrillation status. Additional topics include comparisons of mortality and cardiovascular-related hospitalizations between acoramidis and placebo, as well as analyses of healthcare resource utilization and outcomes related to other therapies. The results are scheduled to be presented at the upcoming conference and have not yet been disclosed.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BBIO":"BridgeBio Pharma, Inc.","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","BK4112":"金融交易所和数据","BK4505":"高瓴资本持仓"},"translate_title":"BridgeBio报告Acoramidis在ATTR-CM研究中可降低死亡率和住院率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"BBIO":0.9},"content_text":"BridgeBio Reports Acoramidis Reduces Mortality and Hospitalizations in ATTR-CM Study\n    \n\nBridgeBio Pharma Inc. announced that data from the ATTRibute-CM study, evaluating its transthyretin stabilizer acoramidis (marketed as Attruby™), will be presented at the American Heart Association (AHA) Scientific Sessions 2025, scheduled for November 7-10, 2025, in New Orleans, LA. Ten moderated digital posters are set to cover various aspects of the ATTRibute-CM study, including the effect of acoramidis on all-cause mortality in patients with the p.V142I (V122I) variant of transthyretin amyloid cardiomyopathy (ATTR-CM), associations between serum transthyretin levels and cardiovascular outcomes, and the impact of acoramidis on clinical outcomes regardless of atrial fibrillation status. Additional topics include comparisons of mortality and cardiovascular-related hospitalizations between acoramidis and placebo, as well as analyses of healthcare resource utilization and outcomes related to other therapies. The results are scheduled to be presented at the upcoming conference and have not yet been disclosed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566844-en) on November 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}